Key facts
- This page summarizes Kathryn Romano's Form 4 filing for Krystal Biotech, Inc. (KRYS).
- 9 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 03 Mar 2026, 18:33.
Kathryn Romano - 27 Feb 2026 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)
- Reporting relationship
- Chief Accounting Officer
- Issuer ticker
- KRYS
- Reported as of
- 27 Feb 2026
- Net transaction value
- -$1,165,991
- SEC form
- 4
- Accepted by SEC
- 03 Mar 2026, 18:33:55 UTC
- Prior SEC filing
- 11 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kathryn Romano
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Kathryn Romano filed Form 4 for Krystal Biotech, Inc. (KRYS) on 03 Mar 2026.
Change
- Previous filing in this sequence was filed on 11 Feb 2026.
- Current net transaction value: -$1,165,991.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001801385
Primary reporting owner
ROMANO KATHRYN
- Relationship
- Chief Accounting Officer
- Address
- C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH
- Signature
- /s/ Kathryn Romano
- Signature date
- 03 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KRYS
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +7,500
- Change %
- +40%
- Price
- $0.000000
- Shares after
- 26,068
- Date
- 27 Feb 2026
- Ownership
- Direct
- Footnotes
- F1
KRYS
transaction
Common Stock
Tax liability
- Transaction value
- $899,138
- Shares
- -3,262
- Change %
- -13%
- Price
- $275.64
- Shares after
- 22,806
- Date
- 27 Feb 2026
- Ownership
- Direct
- Footnotes
- F2, F3
KRYS
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +550
- Change %
- +2.4%
- Price
- $0.000000
- Shares after
- 23,356
- Date
- 27 Feb 2026
- Ownership
- Direct
- Footnotes
- F4
KRYS
transaction
Common Stock
Tax liability
- Transaction value
- $66,154
- Shares
- -240
- Change %
- -1%
- Price
- $275.64
- Shares after
- 23,116
- Date
- 27 Feb 2026
- Ownership
- Direct
- Footnotes
- F3, F5
KRYS
transaction
Common Stock
Sale
- Transaction value
- $200,700
- Shares
- -750
- Change %
- -3.2%
- Price
- $267.60
- Shares after
- 22,366
- Date
- 02 Mar 2026
- Ownership
- Direct
- Footnotes
- F6
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KRYS
transaction
Derivative
Performance Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -7,500
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 27 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,500
- Exercise price
- Footnotes
- F1
KRYS
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -550
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 1,650
- Date
- 27 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 550
- Exercise price
- Footnotes
- F4
KRYS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +13,575
- Change %
- Price
- $0.000000
- Shares after
- 13,575
- Date
- 27 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,575
- Exercise price
- $275.64
- Footnotes
- F7
KRYS
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +5,442
- Change %
- Price
- $0.000000
- Shares after
- 5,442
- Date
- 27 Feb 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,442
- Exercise price
- Footnotes
- F8, F9, F10
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 10 footnotes
Footnote F1
15,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026.
Footnote F2
Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 7,500 RSUs on February 27, 2026.
Footnote F3
The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market.
Footnote F4
2,200 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 550 RSUs, vesting on February 27, 2026.
Footnote F5
Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 550 RSUs on February 27, 2026.
Footnote F6
The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2025. The Rule 10b5-1 trading plan terminated upon completion of the sale of the shares of the Company's common stock reported on this Form 4, which represented the completion of all sales of the Company's common stock subject to the Rule 10b5-1 trading plan.
Footnote F7
The stock options vest in four equal annual installments beginning on February 27, 2027.
Footnote F8
Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date.
Footnote F9
The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates.
Footnote F10
The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027.